BioCryst Partners With Shionogi On Influenza Antiviral In Japan

 
• By Shirley Haley

Shionogi gains development and commercialization rights for peramivir in Japan in deal worth up to $130 million plus royalties for BioCryst.

More from Japan

More from Asia